ArticleAdvances in therapy2026
The Alternative Complement Pathway in IgA Nephropathy: A Podcast for Advanced Practice Providers.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and contributes considerably to the global burden of chronic kidney disease, with up to 50% of patients' disease progressing to kidney failure within 10-20 years of diagnosis. The pathogenesis of IgAN is driven by the deposition of immune complexes containing galactose-deficient immunoglobulin A1 in the glomeruli of the kidney. This deposition activates downstream inflammatory pathways, including the alternative complement pathway, leading to progressive glomerular injury. In this podcast article, a nephrologist and two advanced practice providers discuss the clinical features and pathogenesis of IgAN and explore the importance and clinical implications of alternative complement pathway overactivation in IgAN. The authors also discuss the evolving therapeutic landscape and provide their future perspectives on therapies targeting the underlying disease pathogenesis, including complement inhibitors, as well as the remaining gaps in patient care. PODCAST CONTENT: The podcast video can be downloaded from the article's Figshare page here: https://doi.org/10.6084/m9.figshare.32587806 . Alternatively, you can stream the podcast by searching for 'Adis Journal Podcasts' on your preferred podcast platform. Supplementary file 1 (MP4 225123 kb).
Indexed as
Identifiers
42530828What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.